Aeras

What Aeras does

Aeras is a non-profit biotechnology organization headquartered in Gaithersburg, Maryland, founded in 2003, with 51-100 employees. The organization's stated mission is to advance the development of tuberculosis vaccines to address critical global health challenges, particularly in infectious disease prevention. Its operating focus is narrow and specialized: the clinical development of vaccine candidates targeting Mycobacterium tuberculosis, with the goal of reducing TB disease burden in high-incidence regions.

Aeras's core product is the M72/AS01E tuberculosis vaccine candidate, currently in Phase 3 clinical development in collaboration with GSK. The vaccine has demonstrated 50% efficacy in clinical trials, a clinically significant result given the lack of new TB vaccines in late-stage development globally. The M72/AS01E construct pairs the M72 fusion protein antigen with GSK's AS01E adjuvant system, and the partnership represents a co-development arrangement rather than a licensing deal. No additional pipeline assets, manufacturing capabilities, or platform technologies are disclosed in the available data.

As a non-profit entity, Aeras does not operate a commercial revenue model. No pricing, distribution, or sales channels are disclosed, and no funding rounds, grants, or donor inflows are itemized in the available data. The company's operating status is inferred from its active Phase 3 clinical program and ongoing collaboration with GSK, but no explicit operating statements, management details, or financial disclosures are available. The organization's website (aeras.org) currently displays a default server test page, suggesting minimal public-facing commercial infrastructure.

Name

Aeras

Legal name

Aeras

Website

https://aeras.org

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Aeras is a non-profit biotech organization that develops tuberculosis vaccines, partnering with GSK on the Phase 3 M72/AS01E candidate (50% efficacy). It serves global health markets by addressing unmet needs in TB prevention.

Ownership category

akta.pro rank

Product category

Tuberculosis Vaccines

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Tuberculosis & Mycobacterial Diseases (HLAKAGAH), Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)

Keywords

• Tuberculosis vaccine development
• Infectious disease vaccines
• Clinical stage biotechnology
• Global health vaccines
• Vaccine research nonprofit

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Aeras is a non-profit biotechnology organization developing tuberculosis vaccines for global health. Its primary asset is the M72/AS01E tuberculosis vaccine candidate, currently in Phase 3 clinical trials in collaboration with GSK, which has demonstrated 50% efficacy in preventing tuberculosis disease. The company focuses on advancing this vaccine through late-stage clinical development to address unmet medical needs in TB prevention.

Product overview

Aeras is a biotechnology organization focused on advancing tuberculosis vaccine development. The company's primary product is the M72/AS01E tuberculosis vaccine, developed in partnership with GSK, which is currently in Phase 3 clinical trials showing promising 50% efficacy results. The company's mission centers on addressing critical global health challenges through infectious disease prevention.

Differentiator

Problem solved

Functional benefit

Products and services

• M72/AS01E Tuberculosis Vaccine

Quantifiable outcome

• Phase 3 clinical trial showing 50% efficacy against tuberculosis

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• GSKcoreStrategic or Co-development Partner · 8 January 2026GSK and AERAS are collaborating on a Phase 3 M72/AS01E tuberculosis vaccine trial that has demonstrated 50% efficacy. This represents a strategic co-development partnership focused on addressing a critical unmet medical need in global health.

Scale indicators1 record

Recent moves2 records

Expansion highlights3 records

Direct peers

• Sabin Vaccine Institute: Sabin is a non-profit that develops and advocates for vaccines addressing neglected diseases. It is comparable to Aeras in organizational structure (non-profit, global health focus) and adjacent in mission, though broader across multiple vaccine targets.
• Bill & Melinda Gates Medical Research Institute: Gates MRI is a non-profit biotech developing vaccines and biologics for diseases of the developing world, including TB (BCG-revaccination programs). It is a peer in indication, structure, and donor-aligned mission.
• Bharat Biotech: Bharat Biotech is developing VPM1002, a recombinant BCG TB vaccine candidate, representing one of the most advanced competing TB vaccine programs globally. It is a direct peer in target indication, development stage, and global health mission.
• IAVI: IAVI is a non-profit scientific research organization advancing vaccines and antibodies for infectious diseases including TB and HIV. It is structurally and operationally comparable to Aeras — non-profit, mission-driven, donor-funded, and focused on global health vaccine development.

Broad incumbents

• Emergent BioSolutions: Emergent is a specialty vaccine and biologics manufacturer with public health and infectious disease programs. It is comparable as a broader infectious-disease vaccine developer with similar government/procurement customer base.
• Serum Institute of India: The world's largest vaccine manufacturer by volume, Serum Institute produces BCG and other TB-related vaccines and is a likely future manufacturer/distributor of any approved TB vaccine. It is a broad incumbent in the same commercial ecosystem.
• GSK: GSK is the strategic partner on M72/AS01E and the originator of the AS01E adjuvant platform. As a top-tier global vaccine manufacturer with deep TB expertise and established distribution, GSK is the most directly comparable incumbent in the TB vaccine space and the obvious benchmark for Aeras's program economics.

Emerging players

• BioNTech: BioNTech has publicly explored mRNA-based TB vaccine candidates. While a commercial-stage company, its emerging TB program and mRNA platform make it an emerging peer in next-generation TB vaccine development.
• Novavax: Novavax's protein subunit vaccine platform has been explored for TB applications in academic collaborations. While primarily a commercial-stage company, its technology platform overlap makes it an emerging peer in alternative TB vaccine approaches.

Others

• TuBerculosis Vaccine Initiative (TBVI): TBVI is a non-profit product development partnership advancing new TB vaccines through European and global consortia. It is an ecosystem peer — operating in the same indication, sharing research networks, and representing an alternative organizational model for TB vaccine development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/aerasglobaltb

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aeras